alexa

GET THE APP

Study of Plasma Endostatin Level in Patients with Acute Myeloid Leukemia | OMICS International| Abstract

Journal of Oncology Research and Treatment
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Adv Oncol Res Treat 2016. 1:2,

Study of Plasma Endostatin Level in Patients with Acute Myeloid Leukemia

Haggag R1*, Hussein O2, El Moaty HA2, Omran A2 and Ebian H2
1Medical Oncology Department, Faculty of Medicine, Zagazig University, Sharkia, Egypt
2Clinical Pathology Department, Faculty of Medicine, Zagazig University, Sharkia, Egypt
*Corresponding Author : Haggag R, Department of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia, Egypt, Tel: +201151600020, Email: [email protected]

Received Date: Mar 08, 2016 / Accepted Date: Apr 26, 2016 / Published Date: May 06, 2016

Abstract

Background: Endostatin is a broad spectrum angiogenesis inhibitor and may interfere with the proangiogenic action of growth factors.
Methods: To evaluate the prognostic value of endostatin serum level in acute myeloid leukemia (AML), sixty subjects were included in this study, 30 apparently healthy adult subjects as control (group I) and 30 adult patients with newly diagnosed de novo AML (group II). Estimation of serum endostatin level by ELIZA, at the onset of the disease and after 1 month of induction treatment.
Results: Serum endostatin levels varied widely from 2.1 ng/mL to 7.1 ng/mL (median, 4.1 ng/mL), and the median level was higher in patients with AML compared with patients in the control group (2.6 ng/mL; P<0.001). No significant difference was found between pre-and post-treatment in group II (0.23). The overall survival of patients who had pre-treatment endostatin level ≤50% percentile was significantly longer than patients with pre-treatment endostatin level >50% percentile (p=0.007).According to change of endosatin levels, the overall survival of patients with increased endostatin level was significantly longer than patients with decreased endostatin (p=0.03).
Summary/Conclusion: Inhibition of the angiogenesis may have a role in remission of AML patients.

Keywords: Acute myeloid leukemia; Endostatin; Prognosis; Angiogenesis

Citation: Haggag R, Hussein O, El Moaty HA, Omran A, Ebian H (2016) Study of Plasma Endostatin Level in Patients with Acute Myeloid Leukemia. Adv Oncol Res Treat 1: 107.

Copyright: ©2016 Haggag R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 10387
  • [From(publication date): 6-2016 - Jun 14, 2021]
  • Breakdown by view type
  • HTML page views: 10195
  • PDF downloads: 192
Top